Molecular methods for diagnosing novel coronavirus infection: comparison of loop-mediated isothermal amplification and polymerase chain reaction

Cover Page


Cite item

Full Text

Abstract

Introduction. Currently, the basis for molecular diagnostics of most infections is the use of reverse transcription polymerase chain reaction (RT-PCR). Technologies based on reverse transcription isothermal loop amplification (RT-LAMP) can be used as an alternative to RT-PCR for diagnostic purposes. In this study, we compared the RTLAMP and RT-PCR methods in order to analyze both the advantages and disadvantages of the two approaches.

Material and methods. For the study, we used reagent kits based on RT-PCR and RT-LAMP. The biological material obtained by taking swabs from the mucous membrane of the oropharynx and nasopharynx in patients with symptoms of a new coronavirus infection was used.

Results. We tested 381 RNA samples of the SARS-CoV-2 virus (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) from various patients. The obtained values of the threshold cycle (Ct) for RT-PCR averaged 20.0 ± 3.7 s (1530 ± 300 s), and for RT-LAMP 12.8 ± 3.7 s (550 ± 160 s). Proceeding from the theoretical assumptions, a linear relationship between values obtained in two kits was proposed as a hypothesis; the correlation coefficient was approximately 0.827. At the same time, for samples with a low viral load (VL), the higher Ct values in RT-LAMP did not always correlated with those obtained in RT-PCR.

Discussion. We noted a significant gain in time for analysis using RT-LAMP compared to RT-PCR, which can be important in the context of testing a large number of samples. Being easy to use and boasting short turnaround time, RT-LAMP-based test systems can be used for mass screening in order to identify persons with medium and high VLs who pose the greatest threat of the spread of SARS-CoV-2, while RT-PCR-based diagnostic methods are also suitable for estimation of VL and its dynamics in patients with COVID-19.

Full Text

Introduction

The novel coronavirus infection (COVID-19) caused by the virus known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in Wuhan, Hubei Province, the People’s Republic of China, and then rapidly spread across the world [1][2]. In 2.5 months, on March 11, 2020, the World Health Organization (WHO) declared the beginning of COVID-19 pandemic. Despite numerous epidemic control measures, including long quarantine periods all over the world, as of November 2021, more than 260 million confirmed cases of COVID-19, and more than 5 million deaths had been reported globally (https://www.worldometers.info/coronavirus/). Another serious problem aggravating the situation was the overloaded diagnostic infrastructure; as a result, the existing laboratory facilities were not always able to keep up with a large number of laboratory tests and assessments, which had to be completed within short timeframes, especially during spikes in the incidence. There was a pressing need for new, fastto-perform and accurate test systems for detection of the COVID-19 virus and being of critical importance for the control over the infection spread among the population.

Molecular and genetic methods have a special place in the system of infectious-disease diagnostics and epidemiological surveillance, being overall notable for their high specificity/sensitivity, reproducibility, and short turnaround time. Most significantly, in vitro tests, which are deployed using this diagnostic approach, tend to minimize medical involvement. Solutions based on nucleic acid amplification techniques (NAATs), which include the widely used technique of polymerase chain reaction (PCR), come as better and viable options when the target pathogen belongs to the group of difficult-to-culture or non-culturable types or is present in small amounts.

Today, molecular diagnostics used for most infectious diseases, including novel coronavirus infection is based on reverse transcription polymerase chain reaction (RTPCR) [3][4]. PCR reagent kits are very efficient, showing high sensitivity/specificity in detecting viral nucleic acid in samples from nasal and oropharyngeal swabs. Note that WHO and U.S. Centers for Disease Control and Prevention (CDC) approved using RT-PCR tests as gold standard tests for diagnosing COVID-19 [2][5]. Yet, despite all their advantages underlying their immense popularity and their significant role in laboratory assays and diagnostic analytics, PCR tests have a number of drawbacks and limitations. First of all, they require expensive equipment and a relatively long time for amplification (often from 1 to 2 hrs) [6, 7], and, consequently, a longer turnaround time, considering the sample preparation. In turn, all the above adds to the existing problem of highly overloaded laboratories.

A viable alternative to using RT-PCR for solving diagnostic problems can be offered by techniques based on reverse transcription loop-mediated amplification (RTLAMP) [8–10]. Generally, compared to PCR techniques, loop-mediated amplification does not require thermal cycling and, consequently, expensive special equipment; it is easy to perform and has shorter time to result. RTLAMP technique requires a reverse transcriptase, thermostable DNA polymerase with displacement activity (a large fragment of Bst polymerase from Geobacillus stearothermophilus or Bsm polymerase from Bacillus smithii), and at least 4 primers. RT-LAMP is performed at a constant temperature of around 65 °C [11] and normally takes maximum 30 min, including the reverse transcription process. Furthermore, as has been pointed out in many studies, the RNA extraction, the process common to RT-PCR and RT-LAMP, can be omitted in the latter test; while slightly affecting the sensitivity, such omission can save a lot of time [12–14]. Therefore, RT-LAMP can be seen as an efficient diagnostic tool with the limit of detection ranging from 2 to 100 viral RNA copies per reaction. This method is characterized by variability depending on sample preparation techniques, enzymes and master mixes in use, as well as detection methods [15]. Besides, the application of RT-LAMP reagent kits can offer a fast and affordable solution for increasing the laboratory testing throughput without additional equipment.

Considering a large number of articles discussing the pros and cons of both NAATs without references to publications containing direct comparison results, we compared RT-LAMP and RT-PCR tests using 2 reagent kits developed by the Central Research Institute of Epidemiology of Rospotrebnadzor during 2020–2021. The aim of our experimental study was to analyze advantages and disadvantages of both approaches. Primary attention was given to the assessment of the performance speed, convenience, ease of use, and consistency of results for each method. The estimation of exact parameters of sensitivity/specificity for the kits was beyond the scope of our study, as these parameters are specified in the related documentation.

Material and methods

The study was conducted using biological materials from nasal and oropharyngeal swabs taken from patients having symptoms of novel coronavirus infection. The presence of SARS-CoV-2 RNA in the samples was confirmed through the RT-PCR test using an AmpliSens COVID-19-FL reagent kit (AmpliSens, Central Research Institute of Epidemiology) for detection and quantification of COVID-19 virus genetic material (Registration Certificate RZN 2021/14026). The study was conducted with the informed consent of the patients; the research protocol was approved by the Ethics Committee of the Central Research Institute of Epidemiology (Protocol No. 111 of December 22, 2020). The samples were placed in transport medium (Registration Certificate FSR 2009/05011). The RIBO-prep reagent kit (InterLabService LLC., Russia) (Registration Certificate FSR 2008/03147) was used to extract RNA from clinical samples. The study included a total of 381 samples, though preference was given to the clinical samples with the threshold cycle (Ct) not exceeding 20 (245 samples, 64% of the total number) in the RT-PCR test. Such selection preference was important as these samples were also intended for high throughput sequencing or next generation sequencing (NGS) followed by bioinformatic analysis and by uploading of the obtained data on genomic sequences into the VGARus database (https://genome.crie.ru). The impact of high viral load (VL) and low RNA degradation on the quality of genome reads was also taken in consideration. The NGS-produced data were used for checking primer annealing sites for any impact of the existing mutations on the amplification results. In addition, samples with RTPCR Ct ranging from 25 to 35 were also included in the tests to assess potential deployment of RT-LAMP in analysis of samples with the medium and low VL compared to samples with high Ct values in RT-PCR.

In our tests, we used 2 reagent kits: an AmpliSens COVID-19-FL (Registration Certificate RZN 2021/14026) kit designed for RT-PCR tests and an AmpliSens SARSCoV-2-IT (AmpliSens, Central Research Institute of Epidemiology) (Registration Certificate RZN 2021/14599) kit based on the RT-LAMP technique. The SARS-CoV-2 RNA samples were tested using the above kits in accordance with the manufacturer manuals and the CFX96 Real-Time System (BioRad, United States). The obtained data were analyzed using the Bio-Rad CFX Manager v3.1 software in accordance with the manufacturer manual. Fig. 1 presents a schematic diagram of stages of the study.

Рис. 1. Общая схема проведения исследования.

Первоначально у пациентов с симптомами новой коронавирусной инфекции забирали мазки из рото- и носоглотки. Наличие или отсутствие в биоматериале SARS-CoV-2 подтверждали методом ОТ-ПЦР с применением набора реагентов «АмплиСенс COVID-19-FL». Положительные нативные образцы со значениями Ct, удовлетворяющими условиям эксперимента, повторно использовали для выделения РНК вируса, проведения обратной транскрипции и амплификации.

Fig. 1. General scheme of the study.

Initially, oropharyngeal and nasopharyngeal swabs were taken from patients with symptoms of the new coronavirus infection. The presence or absence of SARSCoV-2 in the biological material was confirmed by RT-PCR using the AmpliSens COVID-19-FL reagent kit. Then, positive native samples with Ct values suitable for the experimental conditions were reused to isolate the virus RNA, and reverse transcription and amplification had been performed.

Results

We have tested 381 SARS-CoV-2 RNA samples from different (by gender, age, type, and severity of the disease) patients with COVID-19 symptoms. The pre-test stage included thawing reagents, preparation, and placing of the reaction mix into tubes, adding RNA samples to it, and, when 96-well PCR plate was used, took ≈40 min both for RT-PCR and for RT-LAMP. The amplification with the CFX96 Real-Time System took 93 min in RT-PCR and 40 min in RT-LAMP. Besides, the time before the detection of the fluorescence signal intensity, including reverse transcription and, in RT-PCR, polymerase activation at 95 °C, was equal to 40 and 5 min for RT-PCR and RT-LAMP, respectively. The Ct values obtained after the amplification averaged 20.0 ± 3.7 (the 1,530 ± 300 s range) for RT-PCR and 12.8 ± 3.7 (the 550 ± 160 s range) for RT-LAMP; note that the specified Ct values for the AmpliSens COVID-19-FL reagent kit do not include 5 “blind” cycles. Thus, the amplification time in two techniques demonstrated the 2.7-fold difference; however, it should be remembered that samples with relatively low Ct values accounted for quite a large proportion and could affect the results.

Fig. 2 presents Ct values for different techniques. It should be noted that the cycles differ in their duration. For RT-PCR and RT-LAMP, 1 cycle is equal to 78 sec and 43 sec, respectively, though, according to the manuals for AmpliSens COVID-19 FL and AmpliSens SARSCoV-2-IT reagent kits, the duration of 1 cycle, net of the fluorescence signal detection time and thermal block temperature change time, is 30 sec. Proceeding from the theoretical assumptions, the linear relationship between Ct values for RT-PCR and RT-LAMP was offered as an alternative hypothesis. The correlation coefficient was ≈0.827, being consistent with the determination coefficient R2 equal to 0.684. Thus, the offered linear regression provides satisfactory explanation of the experimental data and the relationship between RT-PCR Cts and RT-LAMP Cts for both kits.

Рис. 2. Диаграмма рассеяния, демонстрирующая значения пороговых циклов Ct для образцов, исследованных методами ОТ-ИТ и ОТ-ПЦР.

Примечание. Каждый образец проанализирован двумя методами. По оси абсцисс – значения пороговых циклов Ct для ОТ-ИТ; по оси ординат – аналогичные показатели для ОТ-ПЦР. Приведены гистограммы распределения величин Ct для LAMP и ПЦР (выделены зелёным и лиловым цветом соответственно).

Fig. 2. Scatter plot showing Ct values for samples analyzed by RT-LAMP and RT-PCR.

Note. Each sample was analyzed by two methods. The abscissa axis shows the Ct values for RT-LAMP, the ordinate axis shows the same values for RTPCR. Histograms of Ct values distribution for LAMP and PCR (highlighted in green and purple, respectively) are also shown.

As stated above, since these samples were analyzed through high throughput sequencing, most of the biological samples had relatively high VL. To assess the range of applicability of loop-mediated amplification in studies of samples with low VL, we also used the samples where the Ct values estimated by RT-PCR reached 35. With lower VL, the RT-LAMP results are less accurate in showing the content of viral genetic material in the sample due to the number and specificity of the primers as well as due to stochastic annealing processes and concatemers formed in the amplified region. Therefore, for samples with low VL, higher Ct values in RT-LAMP do not always correlate with the values demonstrated in RT-PCR. In addition, note that 2 samples with Ct of 31 and Ct of 35 in RTPCR were negative in RT-LAMP. No cases when sample was positive in the RT LAMP test, while being negative in RT-PCR, were observed.

Discussion

During our study, we compared 2 leading NAATs – RT-PCR and RT-LAMP deployed for detection RNA of the novel coronavirus, SARS-CoV-2, using 2 reagent kits: AmpliSens COVID-19-FL (Registration Certificate RZN 2021/14026) and AmpliSens SARS-CoV-2- IT (Registration Certificate RZN 2021/1459914599). While PCR has remained the most popular method of molecular diagnostics for many years, having proved its efficiency and reliability, loop-mediated isothermal amplification has only recently found wide-scale application in diagnostic laboratories; previously, any related techniques were described mainly in scientific publications. However, the COVID-19 pandemic highlighted the pressing need for faster and more efficient methods of detection of nucleic acids of infectious pathogens, giving an incentive to deployment of non-mainstream, though promising amplification methods in diagnostic practice.

We have tested 381 samples from patients with novel coronavirus infection. The RT-LAMP test is much shorter in its turnaround time than the RT-PCR test, being highly beneficial when large amounts of biological material must be tested within a short time.

The main limitation of this study is that most of the samples were collected from the patients with high VL (low Ct values). One of the reasons is that the same samples were tested using NGS sequencing [16]. Nevertheless, we also included samples with higher (up to 35) RTPCR Ct values in the study. On the whole, the RT-LAMP and RT-PCR results are consistent, though in 2 samples with Ct of 31 and 35 in RT-PCR, the viral RNA was not detected by the RT-LAMP test, which would mean a false-negative test result for the patient. The data obtained during our study show that RT-LAMP is a perfect tool for detection of SARS-CoV-2 in patients with medium and high VL (>5 × 104 copies/ml); however, its sensitivity can be insufficient in cases with VL <2 × 103 copies/ml (low and very low VL).

Concurrently, the unsolved question is what Ct value should be deemed significant with the positive RT-PCR result regarding the transmission of the virus from person to person. Although in long-lasting disease cases, VL values can be higher or lower, depending on the time of collection of biological material, the general tendency is that the highest threat in terms of virus transmission is posed by people with high VL. Based on the studies by different researchers, the chances for SARS-CoV-2 culturing tend to decrease for biomaterial samples where RT-PCR Ct values exceed 25 [17]. It has been found that the likelihood of successful culturing of the above virus can decrease to 8% at RT-PCR Ct >35 [18]. There are published data confirming that the novel coronavirus can be potentially cultured from 70% of samples with Ct ≤25 (RT-PCR), while only <3% samples can be used for successful culturing when Ct >35 (RT-PCR) [19]. Other research groups reported that this virus could not be cultured in samples with Ct >24 (RT-PCR) [20]. In addition, it has been found that RT-PCR tests can detect SARSCoV-2 in patients during several weeks after the symptoms disappeared and there is no risk of virus transmission to another person [20].

Summarizing the above, we can conclude that RTLAMP testing systems make it possible to detect novel coronavirus RNAs in biological samples from patients who can transmit the infectious agent to other people, though, in rare cases, they can produce false-negative results for convalescents having the “residual” VL. Another limitation of LAMP techniques is their need for thorough optimization of a number of parameters applicable to the reaction mix and their lack of quantification, as the amplification of concatemers is not identical to doubling of products during each cycle of amplification in the PCR test [21]. However, these limitations are outweighed by multiple advantages, first of all, the high speed of the analytical process and a wide range of detection methods for amplification products. The molecular LAMP diagnostics gains increasing popularity as a cost-effective tool for detection of novel coronavirus infection and for its epidemiological surveillance [22][23]. Besides, point-of-care RT-LAMP tests for SARS-CoV-2 are currently developed for deployment in remote regions [23][24]. Based on the above, it is obvious that isothermal amplification-based diagnostic systems need further studies with larger numbers of samples and better represented samples with low VL.

Conclusion

The results obtained during our study lead to conclusion that loop-mediated isothermal amplification techniques can be used in laboratory diagnostics for detection of SARS-CoV-2 RNAs in clinical samples. Being easy to use and boasting short turnaround time, RTLAMP testing systems can be used for mass screening to identify people who have relatively high VL and pose the highest threat of novel coronavirus transmission and spread, while RT-PCR-based diagnostic methods are more suitable for estimation of VL and its dynamics in patients with COVID-19, especially in cases with relatively low VL. With the need for testing systems for timely detection of SARS-CoV-2 remaining high, LAMP techniques expand the scope of molecular diagnostics, and, when combined with the PCR test and tests for detection of the respective antigen, add flexibility and efficiency to the epidemiological surveillance of the novel coronavirus spread.

×

About the authors

V. G. Akimkin

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0003-4228-9044

Moscow, 111123, Russia

Russian Federation

V. V. Petrov

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-3503-2366

Moscow, 111123, Russia

Russian Federation

K. V. Krasovitov

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0001-7237-1810

Moscow, 111123, Russia

Russian Federation

N. I. Borisova

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-9672-0648

Moscow, 111123, Russia

Russian Federation

I. A. Kotov

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0003-2416-5689

Moscow, 111123, Russia

Russian Federation

E. N. Rodionova

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0003-0192-1832

Moscow, 111123, Russia

Russian Federation

A. S. Cherkashina

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-1888-4903

Moscow, 111123, Russia

Russian Federation

L. Yu. Kondrasheva

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0002-0147-4262

Moscow, 111123, Russia

Russian Federation

E. V. Tivanova

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Email: fake@neicon.ru
ORCID iD: 0000-0003-1286-2612

Moscow, 111123, Russia

Russian Federation

K. F. Khafizov

FSBI «Central Research Institute for Epidemiology» of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor)

Author for correspondence.
Email: kkhafizov@gmail.com
ORCID iD: 0000-0001-5524-0296

Kamil’ F. Khafizov, Ph.D. (Biol.), Head, Scientific Group for the Development of New Diagnostic Methods, Molecular Diagnostics and Epidemiology Department

Moscow, 111123, Russia

Russian Federation

References

  1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–42. https://doi.org/10.1001/jama.2020.2648
  2. Sharfstein J.M., Becker S.J., Mello M.M. Diagnostic Testing for the Novel Coronavirus. JAMA. 2020; 323(15): 1437–8. https://doi.org/10.1001/jama.2020.3864
  3. Drosten C., Göttig S., Schilling S., Asper M., Panning M., Schmitz H., et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J. Clin. Microbiol. 2002; 40(4): 2323–30. https://doi.org/10.1128/jcm.40.7.2323-2330.2002
  4. Mackay I.M., Arden K.E., Nitsche A. Real-time PCR in virology. Nucleic Acids Res. 2002; 30(6): 1292–305. https://doi.org/10.1093/nar/30.6.1292
  5. Tahamtan A., Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev. Mol. Diagn. 2020; 20(5): 453–4. https://doi.org/10.1080/14737159.2020.1757437
  6. Lu R., Wu X., Wan Z., Li Y., Zuo L., Qin J., et al. Development of a novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Virol. Sin. 2020; 35(3):344–7. https://doi.org/10.1007/s12250-020-00218-1
  7. Jiang M., Pan W., Arasthfer A., Fang W., Ling L., Fang H., et al. Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19. Front. Cell Infect. Microbiol. 2020; 10: 331. https://doi.org/10.3389/fcimb.2020.00331
  8. Notomi T., Okayama H., Masubuchi H., Yonekawa T., Watanabe K., Amino N., et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000; 28(12): E63. https://doi.org/10.1093/nar/28.12.e63
  9. Хафизов К.Ф., Петров В.В., Красовитов К.В., Золкина М.В., Акимкин В.Г. Экспресс-диагностика новой коронавирусной инфекции с помощью реакции петлевой изотермической амплификации. Вопросы вирусологии. 2021; 66(1): 17–28. https://doi.org/10.36233/0507-4088-42
  10. Parida M., Posadas G., Inoue S., Hasebe F., Morita K. Real-time reverse transcription loop-mediated isothermal amplification for rapid detection of West Nile virus. J. Clin. Microbiol. 2004; 42(1):257–63. https://doi.org/10.1128/jcm.42.1.257-263.2004
  11. Zhao Y., Chen F., Li Q., Wang L., Fan C. Isothermal amplification of nucleic acids. Chem. Rev. 2015; 115(22): 12491–545. https://doi.org/10.1021/acs.chemrev.5b00428
  12. Bruno A., de Mora D., Freire-Paspuel B., Rodriguez A.S., Paredes- Espinosa M.B., Olmedo M., et al. Analytical and clinical evaluation of a heat shock SARS-CoV-2 detection method without RNA extraction for N and E genes RT-qPCR. Int. J. Infect. Dis. 2021; 109: 315–20. https://doi.org/10.1016/j.ijid.2021.06.038
  13. Lalli M.A., Langmade J.S., Chen X., Fronick C.C., Sawyer C.S., Burcea L.C., et al. Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification. Clin. Chem. 2021; 67(2):415–24. https://doi.org/10.1093/clinchem/hvaa267
  14. Anastasiou O.E., Holtkamp C., Schäfer M., Schön F., Eis-Hübinger A.M., Krumbholz A. Fast Detection of SARS-CoV-2 RNA Directly from Respiratory Samples Using a Loop-Mediated Isothermal Amplification (LAMP) Test. Viruses. 2021; 13. https://doi.org/10.3390/v13050801
  15. Thompson D., Lei Y. Mini review: Recent progress in RT-LAMP enabled COVID-19 detection. Sensors and Actuators Reports. 2020; 2: 100017. http://dx.doi.org/10.1016/j.snr.2020.100017
  16. Borisova N.I., Kotov I.A., Kolesnikov A.A., Kaptelova V.V., Speranskaya A.S., Kondrasheva L.Yu., et al. Monitoring the spread of the SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) variants in the Moscow region using targeted high-throughput sequencing. Voprosy Virusologii. 2021; 66(4):269–78. https://doi.org/10.36233/0507-4088-72
  17. Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021; 2(1): e13–22. https://doi.org/10.1016/s2666-5247(20)30172-5
  18. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3
  19. La Scola B., Le Bideau M., Andreani J., Hoang V.T., Grimaldier C., Colson P., et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol. Infect. Dis. 2020; 39(6): 1059–61. https://doi.org/10.1007/s10096-020-03913-9
  20. Bullard J., Dust K., Funk D., Strong J.E., Alexander D., Garnett L., et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin. Infect. Dis. 2020; 71(10):2663–6. https://doi.org/10.1093/cid/ciaa638
  21. Mora-Cárdenas E., Marcello A. Switch-on the LAMP to spot Zika. Ann. Transl. Med. 2017; 5(24): 500. https://doi.org/10.21037/atm.2017.10.19
  22. Augustine R., Hasan A., Das S., Ahmed R., Mori Y., Notomi T., et al. Loop-mediated isothermal amplification (LAMP): A rapid, sensitive, specific, and cost-effective point-of-care test for coronaviruses in the context of COVID-19 pandemic. Biology (Basel). 2020; 9(8): 182. https://doi.org/10.3390/biology9080182
  23. Rabe B.A., Cepko C. SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification. Proc. Natl. Acad. Sci. USA. 2020; 117(39):24450–8. https://doi.org/10.1073/pnas.2011221117
  24. Yu L., Wu S., Hao X., Dong X., Mao L., Pelechano V., et al. Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. Clin. Chem. 2020; 66(7): 975–7. https://doi.org/10.1093/clinchem/hvaa102

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Akimkin V.G., Petrov V.V., Krasovitov K.V., Borisova N.I., Kotov I.A., Rodionova E.N., Cherkashina A.S., Kondrasheva L.Y., Tivanova E.V., Khafizov K.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies